MindWalk Holdings (HYFT) Non-cash Items (2021 - 2026)
MindWalk Holdings (HYFT) posted quarterly Non-cash Items of -$2.2 million for Q1 2026, down 116.63% year-over-year from $13.0 million in Q1 2025, and up 68.18% quarter-over-quarter from -$6.8 million in Q4 2025.
MindWalk Holdings (HYFT) Non-cash Items (2021 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Non-cash Items for 6 consecutive years, with -$2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-cash Items fell 116.63% year-over-year to -$2.2 million; the TTM figure through Jan 2026 stood at $7.7 million (down 77.15% YoY), while the FY2024 annual figure was $9.9 million, up 80.03% from the prior year.
- Non-cash Items improved to -$2.2 million in Q1 2026 per HYFT's latest filing, from -$6.8 million in the prior quarter.
- Across five years, Non-cash Items topped out at $13.0 million in Q1 2025 and bottomed at -$12.3 million in Q4 2022.
- Historically, Non-cash Items has averaged $1.9 million across 5 years, with a median of -$56095.8 in 2022.
- Annual changes were most pronounced in 2023 — Non-cash Items tumbled 3878.19% — and 2024, when it soared 1752.47%.
- MindWalk Holdings' Non-cash Items stood at -$12.3 million in 2022, then surged by 93.9% to -$752243.8 in 2023, then jumped by 1752.47% to $12.4 million in 2024, then sank by 154.52% to -$6.8 million in 2025, then surged by 68.18% to -$2.2 million in 2026.
- Business Quant data shows HYFT's Non-cash Items at -$2.2 million in Q1 2026, -$6.8 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -2.16 Mn |
| Jan 31, 2026 | -2.16 Mn |
| Oct 31, 2025 | -6.78 Mn |
| Oct 31, 2025 | -6.78 Mn |
| Jul 31, 2025 | 3.66 Mn |
| Jul 31, 2025 | 3.66 Mn |
| Jan 31, 2025 | 12.97 Mn |
| Jan 31, 2025 | 12.97 Mn |
| Oct 31, 2024 | 12.43 Mn |
| Oct 31, 2024 | 12.43 Mn |
| Jul 31, 2024 | -2.14 Mn |
| Jul 31, 2024 | -2.14 Mn |
| Jan 31, 2024 | 10.39 Mn |
| Jan 31, 2024 | 10.39 Mn |
| Oct 31, 2023 | -752,243.77 |
| Oct 31, 2023 | -752,243.77 |
| Jul 31, 2023 | -896,796.96 |
| Jul 31, 2023 | -896,796.96 |
| Apr 30, 2023 | 7.68 Mn |
| Apr 30, 2023 | 7.68 Mn |